Listen & Watch

1. The "Tides" Have Changed: Outsourcing Oligos And Peptides 3/26/2025

   Shifting demand for oligos and peptides drove innovation in CDMO partnerships and reshaped outsourcing relationships. In this Outsourced Pharma Live panel, industry experts shared best practices for outsourcing these specialized therapeutics, with a focus on capacity, regulatory challenges, and technology transfer.

2. Accelerating mRNA-LNP Development: A Deep Dive Into Analytical & Manufacturing Technology Innovation 3/13/2025

   Advancing RNA Live tackled the challenges of mRNA-LNP CQAs head-on, exploring innovative ways to streamline development and enhance quality at smaller scales.

3. A Deep(er) Dive Into The mRNA/RNA-LNP Outsourcing Paradigm 2/27/2025
4. Navigating The Outsourcing Paradigm For RNA Modalities 1/21/2025

   Though there are an increasing number of CDMOs with mRNA/RNA capabilities/platforms, many of these are better equipped for large-scale, linear mRNA development. In this Advancing RNA Live panel discussion, we explored the state of the outsourcing industry and how mRNA and next-gen RNA modality companies need to evaluate CDMO partners' platforms and technical capabilities today.

5. Achieving Next-Generation mRNA-LNP Therapeutics Delivery 11/6/2024

   It’s impossible to attend an event on the future of RNA therapeutics without hearing about the challenges we’re facing with targeted RNA-LNP delivery. In this final Advancing RNA Live discussion of 2024, we sat down with three LNP experts to parse out the current opportunities and unknowns facing the development of next-generation LNPs.

6. From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain 9/26/2024

   The supply chain for mRNA-based cell and gene therapies presents unique challenges due to the sensitive nature of these products. And, as mRNA technology continues to advance, robust processes and scalable solutions are necessary to meet increasing demand.

7. Can We Do Better? Current & Future Realities of mRNA Process Development 8/7/2024

   There’s been great progress in establishing processes and platforms for linear mRNA vaccines — but where does this current know-how fall short for those exploring linear and next-gen RNA constructs for therapeutic (non-vaccine) products?

8. Opening The "Black Box" Of The mRNA Regulatory Paradigm 5/2/2024

   This Advancing RNA panel discussion covers the broad learnings therapeutics developers can (or can’t) adapt from the previously approved mRNA vaccine products, and what an “ideal” RNA therapeutics regulatory paradigm could look like

9. Got Raw Materials? The State Of The mRNA Supply Chain 2/21/2024

   This discussion delves into how Advancing RNA can address concerns over the current “health” and availability of both small- and large-scale RNA therapeutics.

10. mRNA For Cancer Immunotherapy: 2024 Outlook 12/5/2023

    As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.